Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP.
| Autor: | Li Y; Department of Hematology, Qing-dao Central Hospital, Qing-dao, China. lyyycn@yeah.net., Wang YY, Fei HR, Wang L, Yuan CL |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2015; Vol. 19 (9), pp. 1583-8. |
| Abstrakt: | Objective: This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant human thrombopoietin in treating immune thrombocytopenia (ITP). Patients and Methods: Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 µg/kg/d ih recombinant human thrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment. Results: Among the 14 patients, seven complete responses, six responses, and one no response were obtained, with an overall response of 93%. Conclusions: Low-dose rituximab in combination with rhTPO is effective in treating ITP. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|